{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T09:03:14Z","timestamp":1782464594602,"version":"3.54.5"},"reference-count":29,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2017]]},"DOI":"10.7883\/yoken.jjid.2017.068","type":"journal-article","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T18:02:54Z","timestamp":1505066574000},"page":"616-620","source":"Crossref","is-referenced-by-count":7,"title":["Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones"],"prefix":"10.7883","volume":"70","author":[{"given":"Yuka","family":"Yamagishi","sequence":"first","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Shibata","sequence":"additional","affiliation":[{"name":"Corporate Planning Department, Toyama Chemical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Pharmaceutical & Healthcare Research Laboratories, FUJIFILM Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Nomura","sequence":"additional","affiliation":[{"name":"Product Research Department, Toyama Chemical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Mitsuyama","sequence":"additional","affiliation":[{"name":"Development Division, Toyama Chemical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Aichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","unstructured":"1. Ishii Y. Antibiotic susceptibility testing and breakpoint. \u2013Their problems and future prospects\u2013 Jpn J Chemother. 2011;59:454-59. Japanese."},{"key":"2","unstructured":"2. Clinical &amp; Laboratory Standards Institute. CLSI Guidelines. Available at &lt;http:\/\/clsi.org\/&gt;. Accessed December 27, 2016."},{"key":"3","unstructured":"3. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints. Available at &lt;http:\/\/www.eucast.org\/&gt;. Accessed December 27, 2016."},{"key":"4","unstructured":"4. Saito A, Inamatsu T, Okada J, et al. Report of the review board on antimicrobial agent sensitivity measuring method, the Japan Soc. of Chemotherapy. \u2013Breakpoint in respiratory organ infection and septicemia\u2013 Chemotherapy 1994;42:906-14. Japanese."},{"key":"5","unstructured":"5. Saito A, Inamatsu T, Okada J, et al. Report of the review board on antimicrobial agent sensitivity measuring method, the Japan Soc. of Chemotherapy. Breakpoint in respiratory organ infection and septicemia. \u2013New antimicrobial agents and supplemental information for some agents already released (1997)\u2013 Jpn J Chemother. 1997;45:757-61. Japanese."},{"key":"6","unstructured":"6. Watanabe A, Inamatsu T, Oguri T, et al. Report of the committee on antimicrobial susceptibility testing and the committee of clinical evaluation, the Japan Soc. of Chemotherapy Breakpoint in respiratory organ infection and septicemia. \u2013Supplemental information for some new antimicrobial agents (2005)\u2013 Jpn J Chemother. 2005;53:557-9. Japanese."},{"key":"7","unstructured":"7. Kadota J, Ishii Y, Kusachi S, et al. Report of the breakpoint committee for antimicrobial agents, the Japan Soc. of Chemotherapy. Breakpoint in respiratory organ infection, septicemia and urinary tract infection. \u2013Supplemental information for some new antimicrobial agents (2009)\u2013 Jpn J Chemother. 2009;57:343-45. Japanese."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jones RN, Sader HS, Stilwell MG, et al. Garenoxacin activity against isolates form patients hospitalized with community\u2013acquired pneumonia and multidrug\u2013resistant <i>Streptococcus pneumoniae<\/i>. Diagn Microbiol Infect Dis. 2007;58:1-7.","DOI":"10.1016\/j.diagmicrobio.2007.01.019"},{"key":"9","unstructured":"9. GARENOXACIN (GRNX) Special Issue. Jpn J Chemother. 2007;55. Japanese."},{"key":"10","unstructured":"10. Medical Package Insert. GENINAX Tablets 200 mg (The 15th Edition) Revised April 2015. Japanese."},{"key":"11","unstructured":"11. Medical Package Insert. CRAVIT Tablets 250 mg. CRAVIT Tablets 500 mg. CRAVIT Fine Granule 10%. (The 11th Edition) Revised August 2015. Japanese."},{"key":"12","unstructured":"12. Medical Package Insert. AVELOX Tablets 400 mg. (The 8th Edition) Revised September 2012. Japanese."},{"key":"13","unstructured":"13. Medical Package Insert. GRACEVIT Tablets 50 mg. GRACEVIT Fine Granule 10%. (The 10th Edition) Revised August 2016. Japanese."},{"key":"14","unstructured":"14. Amano A, Matsuzaki K, Kishi N, et al. In vitro activity of sitafloxacin against clinical isolates in 2009. Jpn J Antibiot. 2009;63:411-30. (in Japanese with English abstract)"},{"key":"15","unstructured":"15. Amano A, Matsuzaki K, Kishi N, et al. In vitro activity of sitafloxacin against clinical isolates in 2012. Jpn J Antibiot. 2013;66:311-30. (in Japanese with English abstract)"},{"key":"16","unstructured":"16. Abe N, Fukuda S, Nakamura A, et al. Evaluation of target attainment rate of pazufloxacin mesilate using Monte Carlo simulation method. Jpn J Antibiot. 2010;63:319-25. (in Japanese with English abstract)"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.","DOI":"10.1086\/516284"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Craig WA. Does the dose matter? Clin Infect Dis. 2001;33Suppl 3:S233-7.","DOI":"10.1086\/321854"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against <i>Streptococcus pneumoniae<\/i>. J Antimicrob Chemother. 1999;43:79-86.","DOI":"10.1093\/jac\/43.1.79"},{"key":"20","unstructured":"20. Nakamura T, Shimizu C, Hirakawa K, et al. Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics\/pharmacodynamics theory. Jpn J Antibiot. 2009;62:194-202. (in Japanese with English abstract)"},{"key":"21","unstructured":"21. Totsuka K, Mikamo H, Miyazaki S, et al. PK\u2013PD of antimicrobial agents useful in routine medical care. UNION ACE CORP. 2006;142-151. Japanese."},{"key":"22","unstructured":"22. Craig WA. The role of pharmacodynamics in effective treatment of community-acquired pathogens. Advanced Stud Med. 2002;2:126-34."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy. 2000;46 Suppl 1:6-14.","DOI":"10.1159\/000048487"},{"key":"24","unstructured":"24. Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol. Infect Dis. 2003;22:203-21."},{"key":"25","unstructured":"25. The Japanese Respiratory Society(JRS): The JRS Guidelines for the Management of Community -Acquired Pneumonia in Adults. Tokyo: JRS; 2008. Japanese."},{"key":"26","unstructured":"26. Jean BP. The CLSI Approach to Setting Breakpoints. The 25th Annual Meeting of Japanese Society for Clinical Microbiology; 2014 February 25; Nagoya, Japan. Available at &lt;http:\/\/www.jscm.org\/kokusai\/clsinews.html&gt;. Accessed December 27, 2016."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Mouton JW, Brown DFJ, Apfalter P, et al. The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect. 2012;18:E37-45.","DOI":"10.1111\/j.1469-0691.2011.03752.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Biedenbach DJ, Farrell DJ, Flamm RK, et al. Activity of JNJ\u2013Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2012;39:321-5.","DOI":"10.1016\/j.ijantimicag.2011.11.016"},{"key":"29","unstructured":"29. Yanagihara K, Kadota J, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens Conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: General view of the pathogens&apos; antibacterial susceptibility. J Infect Chemother. 2015;21:410-20."}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/70\/6\/70_JJID.2017.068\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T04:33:11Z","timestamp":1570077191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/70\/6\/70_JJID.2017.068\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2017.068","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}